Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)

SHA:688513 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	584.41	971.4	781.23	830.97	1,051	1,055
Trading Asset Securities	981.76	452.35	741.78	516.36	453.84	570
Cash & Short-Term Investments	1,566	1,424	1,523	1,347	1,505	1,625
Cash Growth	11.14%	-6.52%	13.04%	-10.45%	-7.43%	302.24%
Accounts Receivable	257.32	288.44	177.7	180.92	126.73	151.12
Other Receivables	0.53	0.44	0.66	1.25	0.17	0.42
Receivables	257.85	288.88	178.36	182.17	126.9	151.53
Inventory	224.83	190.09	160.98	140.87	103.68	84.03
Prepaid Expenses	-	4.22	4.1	12.78	3.2	5.31
Other Current Assets	26.32	21.76	16.41	25.97	40.76	27.78
Total Current Assets	2,075	1,929	1,883	1,709	1,779	1,894
Property, Plant & Equipment	1,226	1,249	1,255	1,141	874.59	571.68
Long-Term Investments	99.55	80.71	81.08	46.66	-	-
Other Intangible Assets	33.81	35.6	34.46	34.61	33.71	34.22
Long-Term Deferred Tax Assets	12.86	11.5	8.57	8.73	12.16	8.73
Long-Term Deferred Charges	89.48	77.51	54.92	45.36	12.35	3.42
Other Long-Term Assets	22.17	16.73	29.89	32.09	63.39	18.87
Total Assets	3,559	3,400	3,347	3,018	2,775	2,531
Accounts Payable	141.91	144.35	180.94	156.86	203.92	122.73
Accrued Expenses	37.61	266.85	218.97	190.72	156.1	161.12
Short-Term Debt	95.08	74.44	180.95	105.29	20.02	40.03
Current Portion of Long-Term Debt	4.4	3.67	2.93	-	-	-
Current Income Taxes Payable	37.94	4.62	3.34	1.46	2.71	4.96
Current Unearned Revenue	27.66	38.28	31.98	28.71	10.99	16.47
Other Current Liabilities	248.68	64.12	41.98	46.35	38.72	39.97
Total Current Liabilities	593.27	596.32	661.09	529.39	432.46	385.28
Long-Term Debt	33.75	35.93	39.6	-	-	-
Long-Term Unearned Revenue	63.02	68.25	41.18	42.81	51.03	50.33
Long-Term Deferred Tax Liabilities	2.9	1.7	1.46	0.88	0.12	-
Total Liabilities	692.94	702.21	743.33	573.08	483.6	435.61
Common Stock	176.53	176.53	120.09	120.09	120.09	120.09
Additional Paid-In Capital	1,400	1,388	1,444	1,444	1,444	1,444
Retained Earnings	1,355	1,208	1,040	880.3	727.45	531.05
Treasury Stock	-67.67	-76.22	-1.59	-	-	-
Comprehensive Income & Other	2.19	1.02	0.99	0.02	0.07	0.06
Shareholders' Equity	2,866	2,698	2,603	2,444	2,292	2,095
Total Liabilities & Equity	3,559	3,400	3,347	3,018	2,775	2,531
Total Debt	133.23	114.04	223.48	105.29	20.02	40.03
Net Cash (Debt)	1,433	1,310	1,300	1,242	1,485	1,585
Net Cash Growth	15.35%	0.78%	4.63%	-16.33%	-6.35%	296.95%
Net Cash Per Share	8.14	7.48	7.34	7.03	8.43	10.77
Filing Date Shares Outstanding	174.35	174.08	174.93	176.53	176.53	176.53
Total Common Shares Outstanding	174.35	174.08	176.49	176.53	176.53	176.53
Working Capital	1,482	1,332	1,222	1,180	1,347	1,509
Book Value Per Share	16.44	15.50	14.75	13.85	12.98	11.87
Tangible Book Value	2,832	2,662	2,569	2,410	2,258	2,061
Tangible Book Value Per Share	16.24	15.29	14.56	13.65	12.79	11.68
Buildings	-	775.81	724.27	487.54	152.45	140.27
Machinery	-	678.03	661.8	673.35	279.81	226.86
Construction In Progress	-	189.56	186.26	231.12	637.88	372.73

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.